个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

p-Hydroxylcinnamaldehyde reverses 4NQO-induced esophageal tumorigenesis via the RhoA-MAPK signaling pathway

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Zhao, L.[1] * ; Ma, M.[1] ; Zhang, C.[1] ; Dai, S.[1] ; Huo, B. J.[1] ; Shan, B.[1] ;
机构： [1]The Fourth Hospital of Hebei Medical University, Research Center, Shijiazhuang, China, the People's Republic
出处：
ISSN：

关键词： p-Hydroxylcinnamaldehyde (CMSP) Esophageal squamous cell carcinoma (ESCC) Preneoplastic lesion Immune regulation

语种：
外文
WOS：
中科院分区：
出版当年[2019]版：
大类 | 2 区 医学
小类 | 3 区 免疫学
最新[2025]版：
大类 | 3 区 医学
小类 | 4 区 免疫学
JCR分区：
出版当年[2019]版：
Q2 IMMUNOLOGY
最新[2023]版：
Q2 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者机构： [1]The Fourth Hospital of Hebei Medical University, Research Center, Shijiazhuang, China, the People's Republic
推荐引用方式(GB/T 7714)：
Zhao L.,Ma M.,Zhang C.,et al.p-Hydroxylcinnamaldehyde reverses 4NQO-induced esophageal tumorigenesis via the RhoA-MAPK signaling pathway[J].EUROPEAN JOURNAL OF IMMUNOLOGY.2019,49:1897-1897.
APA：
Zhao, L.,Ma, M.,Zhang, C.,Dai, S.,Huo, B. J.&Shan, B..(2019).p-Hydroxylcinnamaldehyde reverses 4NQO-induced esophageal tumorigenesis via the RhoA-MAPK signaling pathway.EUROPEAN JOURNAL OF IMMUNOLOGY,49,
MLA：
Zhao, L.,et al."p-Hydroxylcinnamaldehyde reverses 4NQO-induced esophageal tumorigenesis via the RhoA-MAPK signaling pathway".EUROPEAN JOURNAL OF IMMUNOLOGY 49.(2019):1897-1897

相关文献

[1]p-Hydroxylcinnamaldehyde slows the progression of 4NQO-induced oesophageal tumourigenesis via the RhoA-MAPK signaling pathway [2]The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China [3]The microbial characteristics of esophageal squamous cell carcinoma (ESCC) and healthy subjects [4]Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC) [5]Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC). [6]The microbial characteristics of esophageal squamous cell carcinoma (ESCC) and healthy subjects. [7]The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China. [8]NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) [9]Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study [10]Tislelizumab (TIS) plus chemotherapy (Chemo)/ chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)

资源点击量：39767 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号